🏅 FDA Orphan Designation
Cuvposa
glycopyrrolate
Manufacturer: Shionogi, Inc.
Indicated for:📚 Neurometabolic disorder due to serine deficiency
Indications & Usage
1 INDICATIONS AND USAGE CUVPOSA is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). CUVPOSA is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). ( 1 )
💙 Support Programs
View all →Cuvposa
Shionogi, Inc.
Glycopyrrolate
Hikma
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.